Topical nepafenac formulations

1. A method of treating ophthalmic inflammatory disorders in a human patient comprising topically administering to the patient a composition consisting of

a) 0.1% (w/v) nepafenac;

b) 0.5% (w/v) carbomer;

c) 0.01% (w/v) tyloxapol;

d) 0.4% (w/v) sodium chloride;

e) 2.4% (w/v) mannitol;

f) a pH-adjusting agent in an amount sufficient to cause the composition to have a pH of 7.3-7.7;

g) 0.005% (w/v) benzalkonium chloride;

h) 0.01% edetate disodium; and

i) purified water.

2. In a method of treating ophthalmic inflammatory disorders in a human patient comprising topically administering to the patient an aqueous suspension composition comprising nepafenac, the improvement wherein the composition consists of

a) 0.1% (w/v) nepafenac;

b) 0.5% (w/v) carbomer;

c) 0.01% (w/v) tyloxapol;

d) 0.4% (w/v) sodium chloride;

e) 2.4% (w/v) mannitol;

f) a pH-adjusting agent in an amount sufficient to cause the composition to have a pH of 7.3-7.7;

g) 0.005% (w/v) benzalkonium chloride;

h) 0.01% edetate disodium; and

i) purified water.